

PART 2 QUALITY DOCUMENTATION

Table of content

2.A Qualitative and Quantitative Particulars of the Constituents

- 2.A.1 Qualitative particulars
- 2.A.2 Usual terminology
- 2.A.3 Quantitative particulars
- 2.A.4 Product development

2.B Description of Manufacturing Method

2.C Production and Control of Starting Materials

- 2.C.1 Starting materials listed in pharmacopoeias
- 2.C.2 Starting materials not listed in a pharmacopoeia

2.D Control Tests During the Manufacturing Process

2.E Control Tests on the Finished Product

- 2.E.1 General characteristics of the finished product
- 2.E.2 Identification of active substance(s)
- 2.E.3 Batch titre or potency
- 2.E.4 Identification and assay of adjuvants
- 2.E.5 Identification and assay of excipient components
- 2.E.6 Safety tests
- 2.E.7 Sterility and purity test
- 2.E.8 Residual humidity
- 2.E.9 Inactivation

2.F Batch to Batch Consistency

2.G S tability Tests

2.H Other Information

Annexes

- [Biblio-1](#) – Part2A
- [Biblio-2](#) – Part2A
- [Report-1](#) – Part2A
- [Report-2](#) – Part2B
- [Report-3](#) – Part2E1
- [Report-4](#) – Part2E2
- [Report-5](#) – Part2E3
- [Report-6](#) – Part2E4
- [Report-7](#) – Part2E6
- [Report-8](#) – Part2E7 & 2E8
- [Report-9](#) – Part2E9
- [Stab-1](#) – Part2G
- [Stab-2](#) – Part2G
- [Tech-1](#) – Part2H (common to 2A, 2B, 2D and 2E)
- [Tech-2](#) – Part2H(common to 2A, 2B, 2D and 2E)

Merial
29 avenue Tony Garnier
69 007 LYON

VACCINE NAME

Part I/II/III/IV
Table of Contents
or Name of file